RxDoctor Payments Data

Razmig Babikian

Family · Duarte, CANPI 1295176394

Payments from drug & device makers

$991in general payments, 2019–2025

Across 45 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$439
  • Merck$188
  • Pfizer$115
  • Mirati Therapeutics, Inc.$40
  • EMD Serono, Inc.$39
  • Daiichi Sankyo Inc.$29
  • plus $141 from 7 others

What the payments were for

  • Food & beverage$91492%
  • Education$778%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$991 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$39,273
Medicare patients
134
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate270$4,393,436
TepmetkoTepotinib Hcl26$624,006
GilotrifAfatinib Dimaleate47$512,831
AlecensaAlectinib Hcl23$411,005
KrazatiAdagrasib18$253,974
RetevmoSelpercatinib14$204,406
EliquisApixaban73$48,562
Entecavir23$910
Dexamethasone47$763
Clindamycin Phosphate17$605
Albuterol Sulfate HfaAlbuterol Sulfate13$561
Pantoprazole Sodium65$525
Nystatin22$520
Minocycline Hcl20$454
Potassium Chloride21$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$439$4,393,436270 claims
EMD Serono, Inc.Tepmetko$39$624,00626 claims
Mirati Therapeutics, Inc.Krazati$40$253,97418 claims
PfizerEliquis, Paxlovid$115$48,56285 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,634 family providers in California.

Other family in Duarte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →